Back to top

Tale of the Tape: Archive

Zacks Equity Research

Implied Volatility Surging for Ladder Capital Corp Stock Options

Investors need to pay close attention to LADR stock based on the movements in the options market lately.

LADRNegative Net Change

Zacks Equity Research

Do Options Traders Know Something About LKQ Stock We Don't?

Investors need to pay close attention to LKQ stock based on the movements in the options market lately.

LKQNegative Net Change

Zacks Equity Research

Is Ezcorp (EZPW) a Solid Growth Stock? 3 Reasons to Think "Yes"

Ezcorp (EZPW) could produce exceptional returns because of its solid growth attributes.

EZPWNegative Net Change

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Dillard's (DDS)

Dillard's (DDS) possesses solid growth attributes, which could help it handily outperform the market.

DDSPositive Net Change

Zacks Equity Research

Is Aramark (ARMK) a Solid Growth Stock? 3 Reasons to Think "Yes"

Aramark (ARMK) is well positioned to outperform the market, as it exhibits above-average growth in financials.

ARMKNegative Net Change

Zacks Equity Research

Cimpress (CMPR) is an Incredible Growth Stock: 3 Reasons Why

Cimpress (CMPR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

CMPRNegative Net Change

Zacks Equity Research

Looking for a Growth Stock? 3 Reasons Why Burlington Stores (BURL) is a Solid Choice

Burlington Stores (BURL) could produce exceptional returns because of its solid growth attributes.

BURLNegative Net Change

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook TTM (TTMI)

TTM (TTMI) is well positioned to outperform the market, as it exhibits above-average growth in financials.

TTMIPositive Net Change

Zacks Equity Research

Implied Volatility Surging for KKR Real Estate Stock Options

Investors need to pay close attention to KREF stock based on the movements in the options market lately.

KREFPositive Net Change

Zacks Equity Research

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why

Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ACXPNegative Net Change